Grace Therapeutics (GRCE) 10% Owner Inc. Buys $15K of Stock

Opaleye Management Inc. bought 7,215 shares of Grace Therapeutics, Inc. (GRCE) on October 12, 2026, for a total value of $14,574.3. This purchase is part of Opaleye's strategy, as it continues to build its stake in the company, which is now over 100,000 shares.

Inside Opaleye Management's Trade

Opaleye Management, a 10% owner, acquired these shares at a price of $2.02 each. This purchase adds to previous buys made on September 29 and October 5, 2026, where they bought 7,849 shares and 60,490 shares, respectively. These transactions indicate a strong belief in Grace Therapeutics' future potential.

Other Institutional Activity in Grace Therapeutics

Several other funds hold shares in Grace Therapeutics. Cerity Partners LLC maintains 849,055 shares valued at about $1.6 million. Eversept Partners, LP has increased its holdings by 16,268 shares, bringing its total to 772,900 shares worth approximately $1.5 million. Vanguard Capital Management LLC also added 10,042 shares, totaling 411,714 shares valued at about $778,139. Meanwhile, Citadel Advisors LLC significantly boosted its holdings by 250,999 shares, now holding 349,740 shares worth about $661,008.

Grace Therapeutics, Inc. Stock Down 3.1%

The stock recently traded around $1.89, which is below its 50-day moving average of $2.12 and 63.5% below its 52-week high of $5.18. It is, however, slightly above its 52-week low of $1.79 by about 5.6%. The stock's current performance reflects ongoing challenges in the biotechnology sector, particularly for firms focused on rare diseases.

Recent Earnings

Grace Therapeutics has not reported any trailing twelve-month revenue, and its earnings per share (EPS) stands at -$1.17. The company has not yet scheduled its next earnings date, leaving investors eager for updates on its financial health.

Insider Buying and Selling at Grace Therapeutics, Inc.

In addition to the recent purchase by Opaleye Management, the firm had previously acquired 7,849 shares at $2.09 on September 29, 2026, and 60,490 shares on October 5, 2026. These earlier transactions further demonstrate Opaleye's commitment to increasing its stake in Grace Therapeutics.

About Grace Therapeutics

Grace Therapeutics, Inc. is engaged in developing and commercializing pharmaceutical products for rare and orphan diseases. Its lead product candidate, GTX-104, is designed to treat aneurysmal subarachnoid hemorrhage. With a small team and operations based in Princeton, NJ, the company is focused on making significant strides in the healthcare sector.

Bottom Line

Investors will be watching closely for Grace Therapeutics' next earnings report and any further insider transactions. Opaleye Management's continued buying suggests confidence in the company's direction, despite challenges in the market.